Amjevita™ (adalimumab-atto) – New biosimilar approval
September 23, 2016 – The FDA approved Amgen’s Amjevita (adalimumab-atto), the fourth biosimilar approved by the FDA. Amjevita is biosimilar to AbbVie’s Humira® (adalimumab) and shares 7 of the 10 indications for Humira.
Download PDF
